BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 26027711)

  • 1. Current treatment options for dermatofibrosarcoma protuberans.
    Rutkowski P; Debiec-Rychter M
    Expert Rev Anticancer Ther; 2015; 15(8):901-9. PubMed ID: 26027711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatofibrosarcoma protuberans: recent clinical progress.
    McArthur G
    Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
    Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
    Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New molecular approaches in dermatofibrosarcoma protuberans].
    Kaya G
    Rev Med Suisse; 2009 Jul; 5(211):1519-24. PubMed ID: 19694363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
    Koseła-Paterczyk H; Rutkowski P
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermatofibrosarcoma Protuberans.
    Allen A; Ahn C; Sangüeza OP
    Dermatol Clin; 2019 Oct; 37(4):483-488. PubMed ID: 31466588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
    McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease.
    McArthur GA
    J Natl Compr Canc Netw; 2007 May; 5(5):557-62. PubMed ID: 17509258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
    Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
    Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management.
    Llombart B; Serra-Guillén C; Monteagudo C; López Guerrero JA; Sanmartín O
    Semin Diagn Pathol; 2013 Feb; 30(1):13-28. PubMed ID: 23327727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular approach in the treatment of dermatofibrosarcoma protuberans].
    Fattoruso SI; Visca P; Lopez M
    Clin Ter; 2008; 159(5):361-7. PubMed ID: 18998038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
    Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
    Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current treatment options in dermatofibrosarcoma protuberans.
    Lemm D; Mügge LO; Mentzel T; Höffken K
    J Cancer Res Clin Oncol; 2009 May; 135(5):653-65. PubMed ID: 19205737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S1 guidelines for dermatofibrosarcoma protuberans (DFSP) - update 2018.
    Ugurel S; Kortmann RD; Mohr P; Mentzel T; Garbe C; Breuninger H; Bauer S; Grabbe S
    J Dtsch Dermatol Ges; 2019 Jun; 17(6):663-668. PubMed ID: 31115967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
    Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
    Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatofibrosarcoma Protuberans: What Is This?
    Vitiello GA; Lee AY; Berman RS
    Surg Clin North Am; 2022 Aug; 102(4):657-665. PubMed ID: 35952694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
    Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S
    Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results.
    Malhotra B; Schuetze SM
    Curr Opin Oncol; 2012 Jul; 24(4):419-24. PubMed ID: 22510939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermatofibrosarcoma Protuberans.
    Reha J; Katz SC
    Surg Clin North Am; 2016 Oct; 96(5):1031-46. PubMed ID: 27542641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution.
    DuBay D; Cimmino V; Lowe L; Johnson TM; Sondak VK
    Cancer; 2004 Mar; 100(5):1008-16. PubMed ID: 14983497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.